Free Trial

Pacira BioSciences Q1 2024 Earnings Report

Pacira BioSciences logo
$22.36 +0.30 (+1.36%)
As of 01/17/2025 04:00 PM Eastern

Pacira BioSciences EPS Results

Actual EPS
$0.42
Consensus EPS
$0.46
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Pacira BioSciences Revenue Results

Actual Revenue
$167.12 million
Expected Revenue
$165.43 million
Beat/Miss
Beat by +$1.69 million
YoY Revenue Growth
N/A

Pacira BioSciences Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Pacira BioSciences Earnings Headlines

The #1 Crypto for AI
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
See More Pacira BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pacira BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacira BioSciences and other key companies, straight to your email.

About Pacira BioSciences

Pacira BioSciences (NASDAQ:PCRX) is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

View Pacira BioSciences Profile

More Earnings Resources from MarketBeat